Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04317105 |
| Title | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | Yes |
| Sponsors | National Cancer Institute (NCI) |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | CAN |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | United States | Details | |
| University of Texas at Austin | Austin | Texas | 78712 | United States | Details | |
| University of Texas Medical Branch | Galveston | Texas | 77555-0565 | United States | Details | |
| M D Anderson Cancer Center | Houston | Texas | 77030 | United States | Details | |
| Virginia Commonwealth University/Massey Cancer Center | Richmond | Virginia | 23298 | United States | Details | |
| University Health Network-Princess Margaret Hospital | Toronto | Ontario | M5G 2M9 | Canada | Details |